Pupillocynetic activity of substance P in systemic sclerosis

Journal of Rheumatology

Volumn 30, Issue 6, 2003, Pages 1231-1237

  Del Rosso, Angela ^a   Bertinotti, Luca ^a   Pietrini, Umberto ^a   Messori, Andrea ^b   Fanciullacci, Marcello ^a   Casale, Roberto ^c   Giacomelli, Roberto ^d   Generini, Sergio ^a   Sicuteri, Riccardo ^a   Pignone, Alberto ^a   Cozzi, Franco ^e   Matucci Cerinic, Marco ^a,f  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c Rehabilitation Inst of Montescano   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f Villa Monna Tessa   (Italy)

Author keywords

Peripheral Nervous System; Pupillometry; Substance P; Systemic Sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; DNA TOPOISOMERASE ANTIBODY; SUBSTANCE P; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INSTILLATION; EYE; FEMALE; HUMAN; MALE; MIOSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN FUNCTION; PUPILLOMETRY; SYSTEMIC SCLEROSIS;

AGED; AUTOANTIBODIES; FEMALE; HUMANS; IRIS; MALE; MIDDLE AGED; NEURONS, AFFERENT; PUPIL; REFLEX, PUPILLARY; SCLERODERMA, SYSTEMIC; SUBSTANCE P;

EID: 0038657609     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Clements PJ, Furst DE. Systemic sclerosis. Baltimore: Williams & Wilkins; 1995.
2. Matucci Cerinic M, Generini S, Pignone A, Casale R. The nervous system in systemic sclerosis: clinical features and pathogenetic mechanisms. Rheum Dis Clin North Am 1996;22:879-92.
3. Lori S, Matucci-Cerinic M, Casale R, et al. Peripheral nervous system involvement in systemic sclerosis: the median nerve as target structure. Clin Exp Rheumatol 1996;14:601-5.
4. Dessein PH, Joffe BI, Metz RM, Millar DL, Lawson M, Stanwix AE. Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Am J Med 1992;93:143-50.
5. Kahaleh BM, Matucci Cerinic M. Raynaud's phenomenon and scleroderma: Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 1995;38:1-4.
6. Matucci Cerinic M, Generini S, Pignone A. New approaches to Raynaud phenomenon. Curr Opin Rheumatol 1997;9:544-56.
7. Hermosillo AG, Ortiz R, Dabague J, Casanova SM, Martinez-Levin N. Autonomic dysfunction in diffuse scleroderma vs CREST: an assessment by computerized heart rate variability. J Rheumatol 1994;21:1849-54.
8. Morelli S, Piccirillo G, Fimognari F, et al. Twenty four hour heart period variability in systemic sclerosis. J Rheumatol 1996;23:643-5.
9. Ferri C, Emdin M, Giuggioli D, et al. Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis. Br J Rheumatol 1997;36:669-76.
10. Akesson A, Ekman R, Prytz H, Sundler F. Gastrointestinal regulatory peptides in systemic sclerosis. Arthritis Rheum 1993;36:698-703.
11. Akesson A, Ekman R. Tissue concentration of gastrointestinal regulatory peptides in the duodenal mucosa in systemic sclerosis. Clin Exp Rheumatol 1998;16:141-8.
12. Weston S, Thumshirn M, Wiste J, Camilleri M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol 1998;93:1085-9.
13. Raszewa M, Hausmanowa-Petrusewicz I, Blaszczyk M, Jablonska S. Sympathetic skin response in scleroderma. Electromyogr Clin Neurophysiol 1991;31:467-72.
14. Lock G, Straub RH, Zeuner M, et al. Association of autonomic nervous dysfunction and esophageal dysmotility in systemic sclerosis. J Rheumatol 1998;25:1330-5.
15. Straub RH, Zeuner M, Lock G, et al. Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis. J Rheumatol 1996;23:87-92.
16. Maggi CA. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol 1995;45:1-98.
17. Matucci Cerinic M. Sensory neuropeptides and rheumatic diseases. Rheum Dis Clin North Am 1993;19:975-91.
18. Jancso N, Jancso-Gabor A, Szolcsanyi J. The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat. Br J Pharmacol 1968;32:32-41.
19. Fortier LA, Nixon AJ. Distributional changes in substance P nociceptive fiber patterns in naturally osteoarthritic articulations. J Rheumatol 1997;24:524-30.
20. Tervo T, Tarkkanen A, Tervo K. Innervation of the human pupillary sphincter muscle by nerve fibers immunoreactive to substance P. Ophthalmic Res 1985;17:111-4.
21. Stone RA, Kuwayama Y. Substance P-like immunoreactive nerves in the human eye. Arch Ophthalmol 1985;103:1207-11.
22. Alessandri M, Fusco BM, Maggi CA, Fanciullacci M. In vivo pupillary constrictor effects of substance P in man. Life Sci 1991;48:2301-8.
23. Andersson SE. Responses to antidromic trigeminal nerve stimulation, SP, NKA, CGRP and capsaicin in the rat eye. Acta Neurol Scand 1987;131:371-6.
24. Anderson JA, Malfroy B, Richard NR, Kullerstrand L, Lucas C, Binder PS. Substance P contracts the human iris sphincter: possible modulation by endogenous enkephalinase. Regul Peptides 1990;29:49-58.
25. Wang ZY, Hakanson R. The rabbit iris sphincter contains NK1 and NK3 but not NK2 receptors: a study with selective agonists and antagonists. Regul Pept 1993;44:269-75.
26. Hall JM, Mitchell D, Morton IK. Neurokinin receptors in the rabbit iris sphincter characterised by novel agonist ligands. Eur J Pharmacol 1991;199:9-14.
27. Grumann-Junior A, Dias MA, Alves RV, Boteon JE, Calixto JB. Mechanisms mediating substance P-induced contraction in the rat iris in vitro. Invest Ophthalmol Vis Sci 2000;41:1861-70.
28. Robertson M, Low PA, Polinsky R, editors. Primer on the autonomic nervous system. San Diego: Academic Press; 1996.
29. Alessandri M, Fusco BM, Briccolani Bandini E, Beatrice S, Fanciullacci M. Dose-dependent myosis by substance P eyedrops in humans. Pharmacol Res 1990;22 Suppl 1:17-8.
30. LeRoy EC, Black C, Fleishmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
31. Shero J, Bordwell BJ, Rothfield NF, Earnshaw WC. High titers of autoantibodies to topoisomerase I (Scl 70) in sera from patients with scleroderma. Science 1986;14:138-40.
32. Vasquez-Abad D, Monteon V, Senecal JL, Walsh S, Rothfield NF. Analysis of the Ig G subclasses of human antitopoisomerase I suggest chronic B cell stimulation. Clin Immunol Immunopathol 1997;84:65-72.
33. Unger WG. Mediation of the ocular response to injury and irritation: peptides versus prostaglandins. Prog Clin Biol Res 1989; 312:293-328.
34. Tsuda K, Masuyama Y. Effects of substance P on norepinephrine release from vascular adrenergic neurons in spontaneously hypertensive rats. Am J Hypertens 1991;4:327-32.
35. Hietarinta M, Lassila O, Hietaharju A. Association of anti-U1RNP- and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). Scand J Rheumatol 1994;23:64-7.
36. Stacher G, Merio R, Budka C, Schneider C, Smolen J, Tappeiner G. Cardiovascular autonomic function, autoantibodies, and esophageal motor activity in patients with systemic sclerosis and mixed connective tissue disease. J Rheumatol 2000;27:692-7.